0 NASDAQ Companies - May 31, 2024Shoals Technologies Group, Inc. Announces Participation in Upcoming Investor EventsPORTLAND, Tenn., May 31, 2024 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (Nasdaq: SHLS), a leading provider of electrical balance […]Read More
0 NASDAQ Companies - May 31, 2024Bitfarms Announces Results of Annual General and Special Meeting of ShareholdersThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, […]Read More
0 NASDAQ Companies - May 31, 2024OPKO Health to Participate in the Jefferies Global Healthcare ConferenceMIAMI, May 31, 2024 (GLOBE NEWSWIRE) — OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in […]Read More
0 TSX Venture News - May 31, 2024MacDonald Mines Provides Update On Assay Results for its Scadding Gold ProjectTORONTO, May 31, 2024 (GLOBE NEWSWIRE) — MacDonald Mines Exploration Ltd. (TSX-V: BMK, OTC: MCDMF) (“MacDonald Mines” or the “Company”), […]Read More
0 NASDAQ Companies - May 31, 2024Moody’s assigns debut AA+.br ratings to Inter, recognizing strong financial positionBELO HORIZONTE, Brazil, May 31, 2024 (GLOBE NEWSWIRE) — Inter&Co (NASDAQ: INTR), the leading financial super app serving over 32 […]Read More
0 NASDAQ Companies - May 31, 2024VEON Announces Its New Board, Names Founder Augie Fabela as ChairmanAmsterdam, 31 May 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online […]Read More
0 TSX Venture News - May 31, 2024Mayfair Gold Chair Letter to Shareholders Ahead of Crucial VoteMATHESON, Ontario, May 31, 2024 (GLOBE NEWSWIRE) — Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) today […]Read More
0 TSX News - May 31, 2024Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation ForumMDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks […]Read More